지중해빈혈 진단 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 최종사용자별, 지역별, 경쟁(2020-2030년)

The Global Thalassemia Diagnostic Market was valued at USD 654.11 million in 2024 and is projected to reach USD 897.26 million by 2030, growing at a CAGR of 5.41%. This market is expanding steadily due to the increasing global prevalence of thalassemia and heightened public awareness surrounding the disease. According to Cureus, approximately 1.5% of the global population-or about 100 million individuals-carry the B-thalassemia gene, with the highest prevalence found in Southeast Asia, the Middle East, and Mediterranean regions. The diagnostic landscape includes a variety of testing methods such as complete blood count, hemoglobin electrophoresis, and DNA analysis. Rising adoption of advanced diagnostic technologies like PCR and genetic testing, known for their precision and sensitivity, is further propelling market growth. Enhanced governmental screening programs and broader access to diagnostic services are also contributing to increased detection and monitoring, supporting long-term disease management.

Key Market Drivers

Rising Prevalence of Thalassemia in Endemic Regions

The increasing prevalence of thalassemia, particularly in high-burden areas such as Southeast Asia, the Middle East, and parts of the Mediterranean, is a primary driver of the Global Thalassemia Diagnostic Market. Thalassemia is a hereditary blood disorder marked by reduced or absent hemoglobin production, often requiring lifelong treatment. WHO estimates that roughly 5% of the global population carries a gene for hemoglobin disorders, including thalassemia.

In countries like India and Pakistan, an estimated 8,000 to 10,000 children are born each year with thalassemia major-a severe form that requires routine transfusions and early diagnosis for effective care. National governments are increasingly rolling out preventive and screening initiatives. For instance, India's Ministry of Health has incorporated thalassemia screening into the Rashtriya Bal Swasthya Karyakram (RBSK), focusing on early genetic disorder detection. Thailand's national prevention strategy, which includes carrier screening and premarital counseling, has significantly reduced the birth rate of severe cases. These efforts are encouraging wider diagnostic adoption, driving market growth.

Key Market Challenges

Limited Access to Diagnostic Services in Low-Income Regions

Despite advances in testing technologies, many low-income and rural regions still lack adequate access to thalassemia diagnostics. This is especially pronounced in Sub-Saharan Africa, Southeast Asia, and certain parts of South America, where healthcare infrastructure remains underdeveloped. According to WHO, numerous high-burden countries have yet to implement national screening policies or structured care programs.

Diagnostic facilities are often concentrated in urban centers, leaving rural populations underserved. Additionally, in many low-income economies, out-of-pocket costs make diagnostic services financially inaccessible. The World Bank reports that over 40% of healthcare expenses in these regions are directly paid by patients, which discourages early screening unless symptoms are severe. The lack of trained personnel, equipment, and government support further compounds the challenge, making early and accurate diagnosis difficult for vulnerable populations.

Key Market Trends

Integration of Genetic Counseling with Diagnostic Services

A notable trend in the Global Thalassemia Diagnostic Market is the integration of genetic counseling into diagnostic workflows, particularly in regions with high carrier prevalence. Genetic counseling helps individuals understand the inheritance patterns, risks, and management options related to thalassemia, enhancing informed decision-making.

Countries such as Cyprus and Iran have achieved success in reducing thalassemia incidence through mandatory premarital screening programs that include counseling. Iran's national initiative reportedly reduced thalassemia births by over 85% within a decade, demonstrating the effectiveness of pairing diagnostic testing with educational support. This trend highlights a shift toward more comprehensive care models that combine early detection with preventative guidance, contributing to improved outcomes and reduced disease burden.

Key Market Players

• Hybribio Limited
• Oasis Diagnostics Corporation
• ViennaLab Diagnostics GmbH
• GENETEK BIOPHARMA GmbH
• Devyser Diagnostics AB
• YANENG BIOSCIENCE (SHENZHEN) CO., LTD.
• BioLab Diagnostics India Private Limited
• NPT Co. Ltd.
• Bio-Rad Laboratories, Inc.
• Chiesi Farmaceutici S.p.A

Report Scope:

In this report, the Global Thalassemia Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thalassemia Diagnostic Market, By Type:

• Complete Blood Cell (CBC) Test
• Hemoglobin Test
• Iron Deficiency Test
• DNA Tests
• Others

Thalassemia Diagnostic Market, By End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Thalassemia Diagnostic Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Thalassemia Diagnostic Market.

Available Customizations:

Global Thalassemia Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Thalassemia Diagnostics Market

6. Clinical Trial Analysis

• 6.1. Ongoing Clinical Trials
• 6.2. Completed Clinical Trials
• 6.3. Terminated Clinical Trials
• 6.4. Breakdown of Pipeline, By Development Phase
• 6.5. Breakdown of Pipeline, By Status
• 6.6. Breakdown of Pipeline, By Study Type
• 6.7. Breakdown of Pipeline, By Region
• 6.8. Clinical Trials Heat Map

7. Global Thalassemia Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Complete Blood Cell (CBC) Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others)
  • 7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 7.2.3. By Region
  • 7.2.4. By Company (2024)
• 7.3. Market Map
  • 7.3.1. By Type
  • 7.3.2. By End User
  • 7.3.3. By Region

8. North America Thalassemia Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Thalassemia Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Canada Thalassemia Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Mexico Thalassemia Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End User

9. Europe Thalassemia Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. Germany Thalassemia Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End User
  • 9.3.2. France Thalassemia Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End User
  • 9.3.3. United Kingdom Thalassemia Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End User
  • 9.3.4. Spain Thalassemia Diagnostics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By End User
  • 9.3.5. Italy Thalassemia Diagnostics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Type
      • 9.3.5.2.2. By End User

10. Asia-Pacific Thalassemia Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Thalassemia Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By End User
  • 10.3.2. India Thalassemia Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By End User
  • 10.3.3. Malaysia Thalassemia Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By End User
  • 10.3.4. Thailand Thalassemia Diagnostics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By End User
  • 10.3.5. Vietnam Thalassemia Diagnostics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Type
      • 10.3.5.2.2. By End User

11. South America Thalassemia Diagnostics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Type
  • 11.2.2. By End User
  • 11.2.3. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Thalassemia Diagnostics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Type
      • 11.3.1.2.2. By End User
  • 11.3.2. Argentina Thalassemia Diagnostics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Type
      • 11.3.2.2.2. By End User
  • 11.3.3. Colombia Thalassemia Diagnostics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Type
      • 11.3.3.2.2. By End User

12. Middle East and Africa Thalassemia Diagnostics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Type
  • 12.2.2. By End User
  • 12.2.3. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. South Africa Thalassemia Diagnostics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Type
      • 12.3.1.2.2. By End User
  • 12.3.2. Saudi Arabia Thalassemia Diagnostics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Type
      • 12.3.2.2.2. By End User
  • 12.3.3. UAE Thalassemia Diagnostics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Type
      • 12.3.3.2.2. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

• 14.1. Product Launches
• 14.2. Mergers & Acquisitions
• 14.3. Recent Developments

15. Global Thalassemia Diagnostics Market: SWOT Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. Hybribio Limited
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Oasis Diagnostics Corporation
• 17.3. ViennaLab Diagnostics GmbH
• 17.4. GENETEK BIOPHARMA GmbH
• 17.5. Devyser Diagnostics AB
• 17.6. YANENG BIOSCIENCE (SHENZHEN) CO.,LTD.
• 17.7. BioLab Diagnostics India Private Limited
• 17.8. NPT Co. Ltd.
• 17.9. Bio-Rad Laboratories, Inc.
• 17.10. Chiesi Farmaceutici S.p.A

18. Strategic Recommendations

19. About Us & Disclaimer